Power Law company profile

Karuna Therapeutics

Biotech & Life Sciences · Boston, United States · Founded 2009 · IPO 2019 Decacorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$11B

Market cap · 2026

Revenue

$654K

Latest reported FY

Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026

Clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions

Investors

8 investors on Karuna Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

PureTech

Steven Paul

ARCH Venture Partners

Wellcome Trust

Series B+ 4 investors entered at this stage

PFM Health Sciences

Pivotal Life Sciences

Alexandria Venture Investments

Eventide Asset Management

Global footprint

Where Karuna Therapeutics has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States94.8%

🇬🇧 United Kingdom2.6%

🇧🇬 Bulgaria2.6%

3 countries shown

Web traffic by country

160 monthly visits
across markets

🇪🇨 Ecuador812.5%

🇺🇸 United States750%

🇬🇷 Greece687.5%

🇬🇧 United Kingdom250%

🇮🇳 India125%

Top 5 markets shown

Patent intelligence

$13M patent portfolio · 13 active families

Estimated portfolio value

$13M

0.11% of market cap · 40.6× smaller than top peer ChemoCentryx ($524M)

13 active patent families

Where Karuna Therapeutics innovates Muscarinics receptorsMedicinal chemistryMuscarinicsXanomelinePharmaceutical drug

Where Karuna Therapeutics concentrates vs peers

Each axis is a top-10 topic across Karuna Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Sentiment on X

What X is saying about Karuna Therapeutics

An AI-synthesized read of the highest-engagement posts about Karuna Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Karuna Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles